Eli Lilly and Company (NYSE:LLY) Holdings Increased by Close Asset Management Ltd

19 Dec 2023, 16:48 by Danessa Lincoln · The Markets Daily

Close Asset Management Ltd grew its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 25.0% during the third quarter, Holdings Channel reports. The institutional investor owned 5,502 shares of the company’s stock after acquiring an additional 1,099 shares during the period. Close Asset Management Ltd’s holdings in Eli Lilly and Company were worth $2,957,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Retirement Group LLC raised its position in shares of Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after buying an additional 35 shares in the last quarter. Cornerstone Planning Group LLC bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $33,000. Raleigh Capital Management Inc. raised its position in shares of Eli Lilly and Company by 156.4% during the 1st quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock worth $34,000 after buying an additional 61 shares in the last quarter. Activest Wealth Management bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $40,000. Finally, VitalStone Financial LLC bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $60,000. 81.38% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $580.00 on Tuesday. The company’s 50 day moving average price is $589.77 and its 200 day moving average price is $533.23. Eli Lilly and Company has a 52 week low of $309.20 and a 52 week high of $629.97. The company has a market capitalization of $550.60 billion, a PE ratio of 105.07, a PEG ratio of 3.48 and a beta of 0.33. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.82 and a current ratio of 1.05.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.18. Eli Lilly and Company had a net margin of 15.55% and a return on equity of 48.12%. The firm had revenue of $9.50 billion for the quarter, compared to the consensus estimate of $8.88 billion. Research analysts expect that Eli Lilly and Company will post 6.61 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 4th. Shareholders of record on Thursday, February 15th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.90%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and Company’s payout ratio is currently 81.88%.

Analyst Ratings Changes

A number of analysts recently commented on LLY shares. Citigroup boosted their target price on shares of Eli Lilly and Company from $525.00 to $675.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Wednesday, November 8th. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $615.00 to $650.00 and gave the stock an “overweight” rating in a report on Monday, October 9th. Deutsche Bank Aktiengesellschaft started coverage on shares of Eli Lilly and Company in a report on Thursday, November 9th. They issued a “hold” rating and a $535.00 target price on the stock. Finally, StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $578.48.

Get Our Latest Report on Eli Lilly and Company

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 670 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $571.10, for a total value of $382,637.00. Following the completion of the sale, the chief accounting officer now directly owns 4,708 shares of the company’s stock, valued at $2,688,738.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, major shareholder Lilly Endowment Inc sold 215,000 shares of the company’s stock in a transaction on Wednesday, October 11th. The shares were sold at an average price of $605.44, for a total transaction of $130,169,600.00. Following the completion of the sale, the insider now directly owns 99,768,810 shares of the company’s stock, valued at approximately $60,404,028,326.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Donald A. Zakrowski sold 670 shares of the company’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $571.10, for a total transaction of $382,637.00. Following the sale, the chief accounting officer now directly owns 4,708 shares of the company’s stock, valued at $2,688,738.80. The disclosure for this sale can be found here. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).